Skye Bioscience, Inc.
Close on Oct 19, 2026
- Market cap
- $60.73M
- P/E (TTM)
- –
- Dividend yield
- –
About Skye Bioscience
Pharmaceutical Preparations, SIC 2834
Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on discovering and developing therapies that target G-protein-coupled receptors. The company specializes in modulating cannabinoid receptor 1 to address metabolic conditions, notably obesity and overweight. Its lead therapeutic candidate is nimacimab, a peripherally restricted antibody evaluated both as a monotherapy and in combination with incretin-based treatments. Because its treatments remain in clinical development and are not commercially marketed, the business currently serves participants within clinical trials and seeks collaborations or licensing partnerships with major pharmaceutical organizations.
The company operates primarily within the United States, where it conducts its clinical studies and evaluates trial participants. Skye Bioscience does not own or operate internal manufacturing facilities, relying instead on third-party contract manufacturing organizations to supply drug candidates for preclinical and clinical evaluations. The company’s headquarters and specific founding details are not stated in the provided text.
Summary of the business section of Skye Bioscience's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Skye Bioscience, Inc.
- Headquarters
- San Diego, CA
- Address
- 11250 El Camino Real, Suite 100 92130
- Phone
- (858) 410-0266
- Employees
- 12, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Nevada
- Fiscal year ends
- December 31
- Auditor
- Marcum LLP, Morristown, New Jersey
Stock & identifiers
- Ticker
- SKYE
- Exchange
- Nasdaq
- Shares outstanding
- 35M, Aug 10, 2026
- Public float
- $129.53M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-8 reverse, Aug 24, 2026; 1-for-250 reverse, Sep 8, 2023; 1-for-250 reverse, Sep 6, 2023
- SEC CIK
- 1516551
- CUSIP
- 83086J309
- ISIN
- US83086J3095
- LEI
- 5493004823BTPRPZ8750
- EIN
- 45-0692882
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Punit Dhillon | Chief Executive Officer, Director | 1,429,166 |
| John P. Sharp | Chief Financial Officer | – |
| Tuan Tu Diep | Chief Operating Officer | 72,833 |
| Christopher Twitty | Chief Scientific Officer | 81,242 |
| Puneet S. Arora | Chief Medical Officer | – |
| Kaitlyn Arsenault | Chief Financial Officer | 167,522 |
| Andrew J. Schwab | Director | 981,269 |
| Deborah H. Charych | Director | – |
| Paul A. Grayson | Director | 259,701 |
| Annalisa Jenkins | Director | – |
| Karen L. Smith | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr. Dhillon | $1.36M | -$148.28K | $882.26K | $19 | – |
| FY2024 Mr. Dhillon | $6.14M | $2.82M | $2.24M | $70 | – |
| FY2023 Mr. Dhillon | $1.81M | $1.25M | $1.27M | $67 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of March 9, 2026, we have a total of 12 full-time employees, four of whom hold a Ph.D or MD degree.”
Corporate history
Events identified from SEC filings